📊 MBIO Key Takeaways
Is MBIO a Good Investment? Thesis Analysis
Mustang Bio is a pre-revenue pharmaceutical company with severe cash burn and deteriorating financial fundamentals. The company is burning approximately $5.3M annually in operating cash flow with zero revenue, making it entirely dependent on cash reserves and debt financing. With only 23 months of cash runway at current burn rates and a debt-to-equity ratio of 1.65x, the company faces significant solvency risk.
Why Buy MBIO? Key Strengths
- Adequate current liquidity ratio of 2.22x providing short-term operational buffer
- Relatively strong cash position of $17.3M enabling near-term development funding
- Positive operating income trend with net loss improving 87.8% YoY showing directional progress
MBIO Investment Risks to Consider
- Zero revenue generation indicates no commercial viability or product commercialization success
- Negative operating cash flow of -$5.3M with negative free cash flow shows ongoing cash depletion
- Debt-to-equity ratio of 1.65x combined with negative interest coverage of -486.4x creates refinancing and solvency risk
- Pre-clinical stage company with no approved products limiting near-term revenue prospects
- Limited insider activity (1 Form 4 filing in 90 days) suggests minimal confidence from insiders
Key Metrics to Watch
- Monthly cash burn rate and runway remaining
- Progress on clinical trial milestones and regulatory filings
- Debt refinancing requirements and covenant compliance
- Operating cash flow trajectory toward sustainability
- Achievement of clinical development milestones
MBIO Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 2.22x current ratio provides a solid financial cushion.
MBIO Profitability Ratios
MBIO vs Healthcare Sector
How MUSTANG BIO, INC. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is MBIO Overvalued or Undervalued?
Based on fundamental analysis, MUSTANG BIO, INC. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
MBIO Balance Sheet & Liquidity
MBIO 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: MUSTANG BIO, INC.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-38.57 indicates the company is currently unprofitable.
MBIO Growth Metrics (YoY)
MBIO Capital Allocation
MBIO SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for MUSTANG BIO, INC. (CIK: 0001680048)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MBIO
What is the AI rating for MBIO?
MUSTANG BIO, INC. (MBIO) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are MBIO's key strengths?
Claude: Adequate current liquidity ratio of 2.22x providing short-term operational buffer. Relatively strong cash position of $17.3M enabling near-term development funding.
What are the risks of investing in MBIO?
Claude: Zero revenue generation indicates no commercial viability or product commercialization success. Negative operating cash flow of -$5.3M with negative free cash flow shows ongoing cash depletion.
What is MBIO's revenue and growth?
MUSTANG BIO, INC. reported revenue of $0.0.
Does MBIO pay dividends?
MUSTANG BIO, INC. does not currently pay dividends.
Where can I find MBIO SEC filings?
Official SEC filings for MUSTANG BIO, INC. (CIK: 0001680048) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MBIO's EPS?
MUSTANG BIO, INC. has a diluted EPS of $-0.39.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MBIO a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, MUSTANG BIO, INC. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is MBIO stock overvalued or undervalued?
Valuation metrics for MBIO: ROE of -20.2% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy MBIO stock in 2026?
Our dual AI analysis gives MUSTANG BIO, INC. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MBIO's free cash flow?
MUSTANG BIO, INC.'s operating cash flow is $-5.3M, with capital expenditures of $0.0.
How does MBIO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -20.2% (avg: 15%), current ratio 2.22 (avg: 2).